Potential strategies against resistance to CAR T-cell therapy in haematological malignancies

Chimeric antigen receptor (CAR) T-cell therapy is a rapidly developing method for adoptive immunotherapy of tumours in recent years. CAR T-cell therapies have demonstrated unprecedented efficacy in the treatment of patients with haematological malignancies. A 90% complete response (CR) rate has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Qing, Zhang, Mingzhi, Li, Zhaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576929/
https://www.ncbi.nlm.nih.gov/pubmed/33133242
http://dx.doi.org/10.1177/1758835920962963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576929/
https://www.ncbi.nlm.nih.gov/pubmed/33133242
http://dx.doi.org/10.1177/1758835920962963

Ejemplares similares